The core problem the review identifies is not a shortage of drugs but a failure of delivery. In urinary tract infection, uropathogenic Escherichia coli adheres to the bladder lining through adhesins such as FimH, invades epithelial cells and builds intracellular bacterial communities that shelter it from antibiotics and immune attack. Catheter-associated infections add another layer: proteins from urine rapidly coat the device surface, forming a conditioning film on which pathogens such as Enterococcus faecalis construct mature biofilms whose extracellular matrix blocks drug diffusion and harbors metabolically quiescent bacteria. Meanwhile, continuous urine washout, cyclic bladder filling and emptying, and the urothelial mucus barrier strip away free drugs before they can act. For interstitial cystitis and chronic prostatitis, the barriers are anatomical: the prostatic capsule, epithelial tight junctions and local microcirculation restrict penetration, while heterogeneous, multifactorial pathology limits oral medications to symptomatic relief.

Nanoparticles attack these bottlenecks through tunable physics. By adjusting particle size, surface charge, material composition and surface ligands, researchers can boost drug loading, prolong local retention, enhance tissue penetration and program controlled release. The review divides the relevant platforms into three classes. Organic nanoparticles, including liposomes, polymeric particles, dendrimers and chitosan, offer biocompatibility, biodegradability and flexible loading, making them well suited to intravesical instillation, mucosal adhesion and delivery of proteins or nucleic acids. Inorganic nanoparticles, such as silver, gold, copper and zinc oxide particles and mesoporous silica, bring intrinsic antibacterial, antioxidant, photothermal or imaging capabilities that do not depend on traditional antibiotic targets. Hybrid systems combine the two, integrating drug delivery, contact killing, anti-adhesive surfaces and sustained release within a single construct.

For recurrent urinary tract infection, the most striking advance targets bacteria hiding inside bladder cells. Tetracycline loaded onto bovine serum albumin-coated nanodiamonds was taken up by urothelial cells, colocalized with intracellular UPEC and released its cargo in acidic endosomes, enhancing bacterial clearance, reducing bladder inflammation and shrinking residual intracellular bacterial communities in infected bladders. Elsewhere, rosemary-oil-loaded chitosan nanophytosomes boosted antibacterial and antibiofilm activity against multidrug-resistant E. coli while easing tissue injury, and liposomes have been shown to protect piperacillin from destruction by staphylococcal beta-lactamase, preserving activity against enzyme-mediated resistance. Ciprofloxacin carried in albumin nanoparticles retained anti-UPEC activity with reduced toxicity to bladder cells and greater effect against mature biofilms than the free drug.

Inorganic nanomaterials bring multimodal killing mechanisms to the fight. Silver nanoparticles release silver ions, generate reactive oxygen species, disrupt membranes and interfere with DNA replication, retaining activity against many drug-resistant strains. Green-synthesized silver particles derived from betel-leaf extract have been shown to silence quorum-sensing systems in Serratia marcescens and Proteus mirabilis, downregulating virulence and biofilm genes. Combining silver nanoparticles with ampicillin or amikacin produced synergistic effects against multidrug-resistant uropathogens at concentrations with low toxicity to human fibroblasts. Zinc oxide nanoparticles inhibited adhesion of fluconazole-resistant Candida albicans by downregulating the ALS1 and ALS3 genes, while silica-tannase nanoconjugates outperformed conventional antibiotics against common urinary pathogens in vitro.

Catheter-associated infection has emerged as the clearest engineering application. A dual-layer nanoengineered catheter deposited silver nanoparticles on silicone and capped them with porous zinc, which regulated ion release, curbed burst effects and, through zinc-mediated reactive oxygen generation, blocked early bacterial adhesion; in a rabbit model it reduced biofilm, encrustation, urethral inflammation and epithelial injury. Beta-casein-capped hollow chitosan nanospheres co-loading a quorum-sensing inhibitor and a bactericide released their payloads sequentially in response to bacterial proteases, suppressing biofilm formation by more than 95 percent and preventing catheter occlusion for 30 days in artificial urine flow. Gold nanoshells immobilized on silicone generated localized heat under near-infrared irradiation, eradicating adherent drug-resistant E. faecalis, while zinc-doped copper oxide coatings delayed the onset of catheter-associated infection in rabbits, with some animals remaining infection-free throughout a seven-day experiment.

Hybrid and biomimetic coatings push the concept further. A superhydrophobic polydopamine-silver-perfluorinated multilayer on silicone catheters combined reduced bacterial contact, delayed biofilm formation and sustained silver release, extending the time to catheter obstruction from roughly 40 hours to about 100 hours. A nanozyme hydrogel built from gold and iron co-doped silver peroxide paired peroxidase-like catalytic hydroxyl radical generation with catalase-like oxygen production, adding anti-inflammatory and microenvironmental modulation to antibacterial action. Biodegradable ureteral stents embedded with silver-gold core-shell nanoparticles created a constantly renewing contact-killing surface that reduced stent-associated infection in a porcine model, illustrating how device interfaces can be engineered for long-term protection.

For noninfectious disease, the emphasis shifts from killing bacteria to repairing barriers and calming chronic inflammation. Thiolated chitosan nanoparticles formed disulfide bonds with bladder mucosal glycoproteins, achieving roughly 14-fold greater adhesion than unmodified particles under urine washout. Cationic liposomes delivered nerve growth factor antisense oligonucleotides to the urothelium with about 40-fold higher uptake than free oligonucleotides, normalizing voiding frequency in a rat model of interstitial cystitis. Hyaluronic acid-based self-assembled nanosheets replenished the damaged glycosaminoglycan layer and reduced bladder inflammation, while curcumin-loaded cerium oxide nanoparticles exploited the reversible cerium redox cycle to scavenge reactive oxygen species, easing pain and restoring urothelial integrity in mice. A nerve-growth-factor-targeting nanocluster-antibody-drug conjugate even combined lesion targeting, fluorescence and CT imaging and immunomodulatory drug release, outperforming standard intravesical therapies in preclinical models.

Chronic prostatitis/chronic pelvic pain syndrome illustrates the precision potential most vividly. Folate-modified, oxidation-responsive nanoparticles loaded with cefpodoxime proxetel homed to folate receptors on activated macrophages in inflamed prostatic tissue, released antibiotic in the reactive-oxygen-rich environment while consuming excess radicals, and reduced bacterial burden, inflammatory cytokines and pelvic pain sensitization in mice. A pH and ROS dual-responsive dexamethasone nanoformulation accumulated in prostatic tissue, attenuated pelvic pain hypersensitivity and was associated with reduced depression-like behavior. Antigen-coupled PLGA nanoparticles carrying a TRPM8-derived peptide induced immune tolerance, raising pain thresholds and lowering inflammatory markers, a strategy fundamentally distinct from conventional analgesia.

The authors are careful to temper enthusiasm with translational reality. Most evidence remains confined to cell cultures and short-term animal studies whose models poorly capture chronicity, recurrence and patient heterogeneity. Long-term safety questions loom large, particularly for metal-based nanomaterials where the window between bacterial killing and urothelial injury must be defined, and for biomimetic systems where donor variability complicates quality control. Manufacturing scale-up, batch consistency, storage stability and premature drug leakage all demand systematic standards. Yet the trajectory is clear: from simple antibiotic carriers toward multifunctional, stimuli-responsive, phenotype-matched platforms that could one day pair with antibiotics, behavioral therapy and neuromodulation as components of individualized care for some of urology’s most persistent inflammatory diseases.

Subject of Research: Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system, including urinary tract infection, catheter-associated infection, interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome

Article Title: Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system: Engineering local delivery, biointerface regulation, and smart responsive therapy

Article References: Wang, W., Ma, J., Hou, C., Chen, J., & Ni, K. (2026). Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system: Engineering local delivery, biointerface regulation, and smart responsive therapy. Materials Today Bio, 41, Article 103673. https://doi.org/10.1016/j.mtbio.2026.103673

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103673

Keywords: nanoparticles, urinary tract infection, catheter-associated UTI, interstitial cystitis, chronic prostatitis, biofilms, drug delivery, silver nanoparticles, stimuli-responsive release, intravesical therapy, antimicrobial resistance, nanomedicine

The research team, led by Wenjing Wang and colleagues, searched PubMed, Scopus, and Web of Science for studies published since 2014, applying the rigorous standards of the PRISMA reporting framework and registering the protocol prospectively with PROSPERO under registration number CRD42025648170. Their aim was deceptively simple but methodologically demanding: to estimate pooled incidence and prevalence of urinary tract infections across different healthcare settings, and then to dissect those estimates by geography, infection setting, and host risk profile. The final dataset included 969,476 participants, a scale that lends considerable statistical weight to the pooled estimates.

The headline finding concerns the stark divide between hospital-acquired and community-acquired infections. Hospital-acquired urinary tract infections, abbreviated HAUTIs in the study, showed a pooled incidence proportion of 0.17, with a 95 percent confidence interval of 0.13 to 0.22, and a pooled prevalence of 0.21, with a confidence interval of 0.16 to 0.25. By comparison, community-acquired urinary tract infections showed a pooled incidence of just 0.08, with a confidence interval of 0.06 to 0.10. In practical terms, roughly one in five hospitalised patients in the included studies had or acquired a urinary tract infection, a figure that underscores how the hospital environment itself, with its invasive devices, immunocompromised patients, and dense microbial ecology, amplifies infection risk.

Within the hospital setting, the single most dangerous factor identified was the urinary catheter. Catheter-associated urinary tract infections emerged as a particularly high-risk category, which is consistent with the well-understood biology of these devices. An indwelling catheter provides bacteria with a direct conduit into the bladder, bypassing the natural flushing action of urination and forming a biofilm on its surface that shields microbes from both immune defences and antibiotics. The meta-analysis confirms that this device-related pathway remains a dominant driver of nosocomial urinary infection, and that catheter stewardship, meaning the avoidance, early removal, and meticulous management of urinary catheters, must sit at the centre of any prevention strategy.

Geography mattered as much as setting. The burden of hospital-acquired urinary tract infections was highest in Asia, Africa, and South America, a pattern that likely reflects a combination of factors including differences in healthcare infrastructure, catheterisation practices, antibiotic access, and surveillance capacity across regions. The authors argue that this regional variation exposes a central weakness in current infection control thinking: a uniform, one-size-fits-all prevention approach cannot adequately serve settings whose baseline risks, resources, and microbial ecologies differ so dramatically. Tailored protocols calibrated to local epidemiology, they suggest, are the realistic path forward.

On the microbiological front, the analysis confirmed what clinical microbiologists have long observed: gram-negative bacteria, and particularly Escherichia coli, dominate the etiology of urinary tract infections. Escherichia coli’s specialised adaptations for the urinary tract, including adhesive pili that bind to bladder epithelial cells and an ability to persist intracellularly, make it an exceptionally effective uropathogen. The predominance of gram-negative organisms carries practical consequences, because rising antimicrobial resistance in this bacterial group, particularly extended-spectrum beta-lactamase production, increasingly constrains empiric treatment choices in many regions.

Beyond setting and geography, the study systematically catalogued host-level risk factors, identifying gender, age, comorbidities, and prior disease history as consistent predictors of infection. Some of the most striking quantitative results came from specific vulnerable populations. Among kidney transplant recipients, those who experienced delayed graft function, a complication in which the transplanted kidney does not immediately work properly, faced a risk ratio of 1.63 for urinary tract infection, with a confidence interval of 1.19 to 2.22. This makes biological sense: impaired graft function alters urinary flow and immune regulation, and transplant patients are simultaneously subjected to immunosuppressive drugs that blunt their defences against bacterial invasion.

Pregnant women formed another clearly delineated high-risk group. The analysis found that lower educational attainment among pregnant women was associated with an elevated risk of urinary tract infection, with a pooled effect estimate of 0.40 and a confidence interval of 0.16 to 0.63. Pregnancy itself predisposes to urinary infection through hormonal relaxation of the ureters and mechanical compression of the urinary tract by the growing uterus, which slows urine flow and allows bacteria more time to establish themselves. Untreated infections in pregnancy can escalate to pyelonephritis and are associated with adverse outcomes for both mother and fetus, which is why identifying modifiable social determinants of risk, such as access to health education, carries real public health value.

The study also highlighted the elderly and people with diabetes as key vulnerable groups. Diabetes impairs immune function and, when poorly controlled, glycosuria creates a nutrient-rich environment in the urine that favours bacterial growth. Ageing, meanwhile, brings anatomical and physiological changes, incomplete bladder emptying, and higher rates of catheterisation and institutional care, all of which compound infection risk. By quantifying these risks within a single analytical framework, the review provides clinicians and policymakers with a stratified map of exactly where preventive effort should be concentrated, rather than spreading resources thinly across the entire patient population.

The broader significance of this work lies in its framing. Rather than treating urinary tract infections as a single homogeneous disease, the authors demonstrate that the burden is sharply stratified by where a patient is treated and who the patient is. That insight supports the development of risk-stratified infection control protocols: aggressive catheter reduction programmes and surveillance in hospitals, targeted screening and education for pregnant women, heightened vigilance in transplant units, and tailored prevention for diabetic and elderly patients. As antimicrobial resistance narrows the treatment options available for gram-negative uropathogens, preventing infections in the first place becomes not merely a convenience but a necessity. This meta-analysis, synthesising evidence from nearly a million people across continents and care settings, offers the clearest evidence yet of where that prevention effort must be aimed.

Subject of Research: Global epidemiology and risk-stratified burden of urinary tract infections across healthcare settings and high-risk populations

Article Title: Risk-stratified epidemiology and global burden of urinary tract infections across healthcare and high-risk populations: a systematic review and meta-analysis

Article References: Wang, W., Huo, N., Ma, H., Li, X., & Wang, Y. (2026). Risk-stratified epidemiology and global burden of urinary tract infections across healthcare and high-risk populations: a systematic review and meta-analysis. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14395-z

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14395-z

Keywords: urinary tract infection, hospital-acquired infection, catheter-associated UTI, meta-analysis, Escherichia coli, kidney transplant, pregnancy, diabetes, infection control, antimicrobial resistance, global health burden, risk factors